Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Joinn Laboratories (China) Co Quick Ratio?
Joinn Laboratories (China) CoSHSE:603127 +3.72%78 Quick Ratio is 2.78 as of Mar. 2026, which is 45% above its 10-year median of 1.92. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.43 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks better than 66.67% on this metric.
Joinn Laboratories (China) Co has a quick ratio of 2.78. It generally indicates good short-term financial strength.
The historical rank and industry rank for Joinn Laboratories (China) Co's Quick Ratio or its related term are showing as below:
SHSE:603127'
s Quick Ratio Range Over the Past 10 Years
Min: 0.7 Med: 1.92 Max: 6.95
Current: 2.78
During the past 13 years, Joinn Laboratories (China) Co's highest Quick Ratio was 6.95. The lowest was 0.70. And the median was 1.92.
SHSE:603127's Quick Ratio is ranked better than 66.67% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.74
vs SHSE:603127: 2.78
Joinn Laboratories (China) Co (SHSE:603127) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Joinn Laboratories (China) Co Quick Ratio Related Terms
Joinn Laboratories (China) Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603127 vs TMO, DHR, IDXX: Quick Ratio Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Quick Ratio falls into.
Joinn Laboratories (China) Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co (SHSE:603127) has a Quick Ratio of 2.78 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Joinn Laboratories (China) Co and its competitors. This is 45% above median its historical median of 1.92. Over the past decade, Joinn Laboratories (China) Co's Quick Ratio has ranged from 0.70 to 6.95. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #71 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 33.3%.
Is Joinn Laboratories (China) Co's Quick Ratio too high?
Joinn Laboratories (China) Co's current Quick Ratio of 2.78 is 45% above median its 10-year median of 1.92. Over the past 10 years, this metric has ranged from a low of 0.70 to a high of 6.95. The Medical Diagnostics & Research industry median Quick Ratio is 1.74. Joinn Laboratories (China) Co's value of 2.78 is 59.8% above this industry median. Based on the distribution chart, Joinn Laboratories (China) Co ranks #71 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #71 out of 213 companies for Quick Ratio. This puts Joinn Laboratories (China) Co in the upper half of its industry. The industry median Quick Ratio is 1.74. Joinn Laboratories (China) Co's value of 2.78 is 59.8% above this benchmark. Historically, Joinn Laboratories (China) Co's own Quick Ratio has ranged from 0.70 to 6.95 over the past decade. While the company's 10-year median is 1.92 vs. the industry median of 1.74, Joinn Laboratories (China) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.74, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joinn Laboratories (China) Co's current Quick Ratio of 2.78 is 59.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Joinn Laboratories (China) Co and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joinn Laboratories (China) Co's current Quick Ratio is 2.78, which is 45% above median its own 10-year median of 1.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current Quick Ratio is 2.78, which is 45% above median its 10-year median of 1.92 and 59.8% above the Medical Diagnostics & Research industry median of 1.74. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Quick Ratio is 2.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Quick Ratio: 2.78 (45% above median its 10-year median of 1.92)
GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
Industry Position: 59.8% above the Medical Diagnostics & Research median (#71 of 213)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
